Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Crinone 8% Intravaginal Gel and IM Progesterone Supplementation for In Vitro Fertilization (IVF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women of reproductive age (21-39) with infertility who are appropriate candidates for IVF/ET and have an FSH \< 15 mIU/ml~* Women 21 to 39 years of age who have been assigned to stimulation of 2 to 8 amps of Luteal Lupron/FSH or Luteal Lupron FSH/HMG.~Exclusion Criteria:~* Women who have had more than 3 previous IVF/ET cycles

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Study Arms:
- Crinone 8% Vaginal Gel (Type: ACTIVE_COMPARATOR): Crinone 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) once a day beginning the second day following oocyte retrieval (Study Group A) continuing until the pregnancy test is negative or until the 10th week of pregnancy.
- Intramuscular Progesterone (Type: ACTIVE_COMPARATOR): Progesterone-50 mg intramuscularly once a day beginning the day after oocyte retrieval continuing until the pregnancy test is negative or if positive, switching to Crinone 8% intravaginal gel until the 10th week of pregnancy.~.

Based on this trial design, predict the completion outcome and termination type (if applicable).